Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors

Show full item record



Permalink

http://hdl.handle.net/10138/317829

Citation

Cervera-Carrascon , V , Quixabeira , D C A , Havunen , R , Santos , J M , Kutvonen , E , Clubb , J H A , Siurala , M , Heiniö , C , Zafar , S , Koivula , T , Lumen , D , Vaha , M , Garcia-Horsman , A , Airaksinen , A J , Sorsa , S , Anttila , M , Hukkanen , V , Kanerva , A & Hemminki , A 2020 , ' Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors ' , Molecular Therapy - Oncolytics , vol. 17 , pp. 47-60 . https://doi.org/10.1016/j.omto.2020.03.003

Title: Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors
Author: Cervera-Carrascon, Victor; Quixabeira, Dafne C.A.; Havunen, Riikka; Santos, Joao M.; Kutvonen, Emma; Clubb, James H.A.; Siurala, Mikko; Heiniö, Camilla; Zafar, Sadia; Koivula, Teija; Lumen, Dave; Vaha, Marjo; Garcia-Horsman, Arturo; Airaksinen, Anu J.; Sorsa, Suvi; Anttila, Marjukka; Hukkanen, Veijo; Kanerva, Anna; Hemminki, Akseli
Contributor organization: Department of Pathology
TRIMM - Translational Immunology Research Program
University of Helsinki
Research Programs Unit
Medicum
HUS Comprehensive Cancer Center
Helsinki In Vivo Animal Imaging Platform (HAIP)
Tracers in Molecular Imaging (TRIM)
Department of Chemistry
Laboratory of Radiochemistry (-2016)
Division of Pharmacology and Pharmacotherapy
Regenerative pharmacology group
HUS Gynecology and Obstetrics
Clinicum
Department of Obstetrics and Gynecology
Helsinki University Hospital Area
Department of Oncology
Date: 2020-06-26
Language: eng
Number of pages: 14
Belongs to series: Molecular Therapy - Oncolytics
ISSN: 2372-7705
DOI: https://doi.org/10.1016/j.omto.2020.03.003
URI: http://hdl.handle.net/10138/317829
Abstract: Despite some promising results, the majority of patients do not benefit from T-cell therapies, as tumors prevent T-cells from entering the tumor, shut down their activity, or downregulate key antigens. Due to their nature and mechanism of action, oncolytic viruses have features that can help overcome many of the barriers currently facing T-cell therapies of solid tumors. This study aims to understand how four different oncolytic viruses (adenovirus, vaccinia virus, herpes simplex virus and reovirus) perform in that task. For that purpose, an immunocompetent in vivo tumor model featuring adoptive tumor-infiltrating lymphocyte (TIL) therapy was used. Tumor growth control (p
Subject: ADENOVIRUS
ANTITUMOR EFFICACY
CANCER
CARCINOMA
COMBINATION
EPITOPES
IMMUNITY
REOVIRUS
REPLICATION
SUPPRESSION
116 Chemical sciences
319 Forensic science and other medical sciences
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: acceptedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S2372770520300243_main.pdf 5.166Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record